Jefferies Financial Group set a GBX 6,800 ($88.85) price target on Reckitt Benckiser Group (LON:RB) in a report released on Wednesday morning. The brokerage currently has a neutral rating on the stock.
A number of other research analysts also recently commented on RB. Credit Suisse Group set a GBX 5,850 ($76.44) price objective on shares of Reckitt Benckiser Group and gave the company a sell rating in a research report on Wednesday, September 19th. JPMorgan Chase & Co. set a GBX 9,000 ($117.60) price objective on shares of Reckitt Benckiser Group and gave the company a buy rating in a research report on Tuesday, September 25th. Morgan Stanley lifted their price objective on shares of Reckitt Benckiser Group from GBX 8,500 ($111.07) to GBX 8,800 ($114.99) and gave the company an overweight rating in a research report on Tuesday, October 2nd. Sanford C. Bernstein set a GBX 8,200 ($107.15) price objective on shares of Reckitt Benckiser Group and gave the company a buy rating in a research report on Thursday, October 4th. Finally, Goldman Sachs Group set a GBX 7,025 ($91.79) price objective on shares of Reckitt Benckiser Group and gave the company a neutral rating in a research report on Monday, October 8th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of GBX 7,065.26 ($92.32).
Shares of RB opened at GBX 5,978 ($78.11) on Wednesday. Reckitt Benckiser Group has a one year low of GBX 5,562 ($72.68) and a one year high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.